Lower blood pressure is indeed better, according to an analysis of the effects of genetic variants.
Blood pressure (BP) targets continue to generate lots of discussion and even confusion. For further insights, investigators made use of UK Biobank data to conduct mendelian randomization analyses examining whether BP has a nonlinear effect on cardiovascular risk. These types of studies leverage randomly allocated genetic variants, in this case variants associated with BP levels, to determine differences in risk.
The 255,714 participants did not have baseline cardiovascular disease (CVD) and were not taking antihypertensive medications. Over a maximum of 12 years, they experienced 10,606 incident CVD events (8430 coronary artery disease events and 2176 stroke events). The genetically proxied systolic and diastolic BPs were strongly associated…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association